Zanamivir for influenza

Drug and Therapeutics Bulletin

Volumn 37, Issue 11, 1999, Pages 81-84

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZANAMIVIR;

DRUG COST; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; SHORT SURVEY; WHEEZING;

EID: 0032720213     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Department of Health, Welsh Office, Scottish Office Department of Health, DHSS (Northern Ireland). Immunisation against infectious disease. London: HMSO, 1996.
2. Curwen M, Dunnell K, Ashley J. Hidden influenza deaths. BMJ 1990; 300: 896.
3. Fleming DM. The impact of three influenza epidemics on primary care in England and Wales. Pharmacoeconomics 1996; 9 (suppl 3): 38-45.
4. National Institute for Clinical Excellence. Guidance to the NHS on zanamivir (Relenza). October 1999.
5. Stephenson I, Nicholson KG. Chemotherapeutic control of influenza. J Antimicrob Chemother 1999; 44: 6-10.
6. Fleming DM, Zambon M, Bartelds AIM, de Jong JC. The duration and magnitude of influenza epidemics: A study of surveillance data from sentinel general practices in England, Wales and the Netherlands. Eur J Epidemiol 1999; 15: 467-73.
7. Woods J M, Bethell RC, Coates JAV et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9.
8. von Itzstein M, Wu W-Y, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23.
9. Relenza. Summary of product characteristics. GlaxoWellcome UK Limited. July 1999.
10. R 10. Hayden FG, Osterhaus ADME, Treanor JJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337: 874-80.
11. R 11. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81.
12. R 12. Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61.
13. R 13. Makela MJ, Pauksens K, Rostila T et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor Zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European Study. J Infection. In press.
14. Colacino JM, Laver WG, Air GM. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect Dis 1997; 176 (suppl 1): S66-8.
15. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257-62.
16. th report [session 1997-8]: Resistance to antibiotics and other antimicrobial agents. [HL] 81-I. London: The Stationery Office, 1998.
17. Tackling antimicrobial resistance. DTB 1999; 37: 9-16.